ASH 2024: AML
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
Advertisement
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.